2024
Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma
Lu B, Lucca L, Lewis W, Wang J, Nogueira C, Heer S, Rayon-Estrada V, Axisa P, Reeves S, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair F, Kluger H, Hafler D. Circulating tumor-reactive KIR+CD8+ T cells suppress anti-tumor immunity in patients with melanoma. Nature Immunology 2024, 1-10. PMID: 39609626, DOI: 10.1038/s41590-024-02023-4.Peer-Reviewed Original ResearchCD8+ T cellsAnti-tumor immunityRegulatory T cellsT cellsSubpopulation of CD8+ T cellsCytotoxic CD8+ T cellsHuman CD8+ T cellsTumor antigen-specific CD8Impaired anti-tumor immunityTumor antigen-specificPoor overall survivalTumor rejectionKIR expressionOverall survivalTumor antigensImmune evasionCellular mediatorsHuman cancersCD8MelanomaTumorTranscriptional programsFunctional heterogeneityImmunityPatients
2016
Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient
Bhatla T, Dandekar S, Lu B, Wang J, Han E, Bitterman D, Jones C, Evensen N, Magid M, Meyer J, Carroll W. Genomic Characterization of Poorly Differentiated Neuroendocrine Carcinoma in a Pediatric Patient. Journal Of Pediatric Hematology/Oncology 2016, 38: e21-e25. PMID: 26558807, PMCID: PMC4681625, DOI: 10.1097/mph.0000000000000463.Peer-Reviewed Original ResearchConceptsNeuroendocrine carcinomaRare tumorPediatric patientsPoor-differentiated neuroendocrine carcinomasMediastinal neuroendocrine carcinomaPrimary neuroendocrine carcinomaStandard treatment approachLack of standardized treatment approachWhole-exome sequencingLOH regionsGenomic characterizationExome sequencingSomatic variantsHRAS geneTumor tissuesMolecular taxonomyGenomic landscapeSomatic mutationsTumorTreatment approachesTherapeutic targetInvestigation of therapeutic targetsCarcinomaPatientsLOH